The efficacy of evolocumab on thin-fiber cap plaque in patients with very high-risk ASCVD: a randomized controlled trial

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000032570

Enrollment

Unknown

Registered

2020-05-02

Start date

2020-05-06

Completion date

Unknown

Last updated

2020-05-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiovascular disease

Interventions

experimental group:Atorvastatin 40mg/day combined with evolocumab 140mg subcutaneous injection once every 2 weeks

control group:Atorvastatin 40mg/day

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients with very high-risk ASCVD undergoing coronary angiography, very high-risk ASCVD was defined according to the 2018 American Lipid Guidelines; 2. Atorvastatin 20mg/day for LDL-C still >= 1.8mmol/L; 3. Patients with TCFA detected by OCT (fiber cap thickness = 20 years on coronary angiography.

Exclusion criteria

Exclusion criteria: 1. Patients who have used pcsk9i; 2. Patients with contraindications of elouzumab / statins, including statins intolerance; 3. Patients with known history of hemorrhagic stroke; 4. Patients who are undergoing blood component extraction or other new technologies to reduce blood lipid; 5. Patients with life expectancy < 1 year.

Design outcomes

Primary

Measure	Time frame
Fiber cap thickness of TCFA;	—

Secondary

Measure	Time frame
lipid arc;Lipid core length;Macrophage infiltration;LDL-C;hs-CRP;	—

Countries

China

Contacts

Public ContactNan Nan

Beijing Anzhen Hospital Affiliated to Capital Medical University

13910096973@139.com+86 13910096973

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 5, 2026